The group had a bad week after turmoil at the FDA, continuing a long period of underperformance following the pandemic.

The landscape of drug discovery has been dramatically shifting, thanks in large part to the influence of artificial intelligence (AI).

Plex Research is partnering with Ginkgo Bioworks to use AI to deepen understanding of the mechanisms of action of existing ...

Ginkgo Bioworks (DNA) is down -4.8%, or -27c to $5.39.Don't Miss Our End of Quarter Offers: Discover the latest stocks recommended by top Wall ...

We recently published a list of 8 Best Gene-Editing Stocks to Buy. In this article, we are going to take a look at where ...

Gene editing is an advanced medical technique within gene therapy that involves precisely modifying an individual’s DNA to ...

Charles Schwab Investment Management Inc. increased its position in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA – Free Report) ...

Spread the love Introduction The biotechnology industry continues to be at the forefront of scientific innovation, driving ...

In the closing of the recent trading day, Ginkgo Bioworks Holdings, Inc. (DNA) stood at $6.59, denoting a -0.9% change from the preceding trading day.

Latest data shows the largest indicative borrow rate increases among liquid option names include: Ginkgo Bioworks (DNA) 7.32% +1.48, Kingsoft ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Detailed price information for Ginkgo Bioworks Hldgs Inc (DNA-N) from The Globe and Mail including charting and trades.